TAIKO PHARMACEUTICAL CO.,LTD. (4574.T) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	6.2B	6.4B	6.3B	6.1B	5.0B
Cost of Revenue	415.0M	2.9B	2.6B	3.5B	4.0B
Gross Profit	500.0M	3.5B	3.7B	2.6B	1.1B
Operating Expenses
R&D Expense	—	—	—	—	—
SG&A Expense	598.0M	3.0B	3.0B	3.6B	4.2B
General & Admin Expense	—	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	—	—	—	—	—
Total Operating Expenses	598.0M	3.0B	3.0B	3.6B	4.2B
Cost and Expenses	5.8B	5.9B	5.7B	7.1B	8.1B
Operating Income (EBIT)	317.0M	459.0M	629.0M	(1.0B)	(3.1B)
Non-Operating
Interest Income	9.0M	16.0M	30.0M	25.0M	5.0M
Interest Expense	—	5.0M	8.0M	8.0M	10.0M
Net Interest Income	9.0M	11.0M	22.0M	17.0M	(5.0M)
Other Non-Op Income/Expense	5.0M	23.0M	58.0M	(243.0M)	(274.0M)
Non-Operating Income (excl Interest)	1.0M	21.0M	56.0M	57.0M	104.0M
EBT (Pre-Tax Income)	(94.0M)	958.0M	565.0M	(3.6B)	(4.9B)
Income Tax Expense	—	34.0M	(332.0M)	47.0M	25.0M
Bottom Line
Net Income	536.0M	923.0M	898.0M	(3.6B)	(4.9B)
Earnings from Cont. Ops	—	—	—	—	—
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	536.0M	923.0M	898.0M	(3.6B)	(4.9B)
Per Share
Basic EPS	¥11	¥18	¥18	(¥76)	(¥112)
Diluted EPS	¥11	—	—	—	—
Revenue Per Share	¥123	¥127	¥125	¥129	¥116
Shares
Basic Shares Outstanding	50.3M	50.2M	50.2M	47.4M	43.6M
Diluted Shares Outstanding	—	—	—	—	—
Profitability Metrics
EBITDA	—	724.0M	885.0M	(301.0M)	(2.3B)
D&A	—	265.0M	256.0M	704.0M	737.0M
EBIT	317.0M	459.0M	629.0M	(1.0B)	(3.1B)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026